{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:15:39Z","timestamp":1769883339404,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2025.106297","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T12:23:34Z","timestamp":1737980614000},"page":"106297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study"],"prefix":"10.1016","volume":"94","author":[{"given":"Raed","family":"Alroughani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasem","family":"Al-Hashel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Farouk Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106297_bib0001","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106297_bib0002","article-title":"No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score\u2013matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Ther","volume":"14","author":"Butzkueven","year":"2021","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106297_bib0003","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2025.106297_bib0004","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcph.1737","article-title":"Modeling the efficacy of Natalizumab in multiple sclerosis patients who switch from every-4-week dosing to extended-interval dosing","volume":"61","author":"Chang","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2025.106297_bib0005","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","article-title":"Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis","volume":"91","author":"Chisari","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2025.106297_bib0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the interval of Natalizumab dosing: is efficacy preserved?","volume":"17","author":"Clerico","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106297_bib0007","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s40265-023-01942-0","article-title":"Escalation versus induction\/high-efficacy treatment strategies for relapsing multiple sclerosis: which is best for patients?","volume":"83","author":"Edan","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2025.106297_bib0008","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2025.106297_bib0009","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing\u2013Remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS. Drugs."},{"key":"10.1016\/j.msard.2025.106297_bib0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.msard.2018.09.008","article-title":"Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review","volume":"26","author":"Gasim","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106297_bib0011","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2025.106297_bib0012","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1756285617708911","article-title":"MRI in the assessment and monitoring of multiple sclerosis: an update on best practice. Ther","volume":"10","author":"Kaunzner","year":"2017","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106297_bib0013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/nmt-2021-0038","article-title":"Healthcare resource utilization and costs for extended interval dosing of Natalizumab in multiple sclerosis","volume":"12","author":"Moccia","year":"2022","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2025.106297_bib0014","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of Natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2025.106297_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200166","article-title":"Natalizumab treatment induces proinflammatory CD4 T cells preferentially in the integrin \u03b27+ compartment","volume":"10","author":"Nguyen Ky","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflammation."},{"key":"10.1016\/j.msard.2025.106297_bib0016","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/NAN.0000000000000519","article-title":"Practical clinical guidelines for Natalizumab treatment in patients with relapsing multiple sclerosis","volume":"46","author":"O'Leary","year":"2023","journal-title":"J. Infus. Nurs."},{"key":"10.1016\/j.msard.2025.106297_bib0017","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40120-023-00440-5","article-title":"Real-world effectiveness of Natalizumab extended interval dosing in a French cohort","volume":"12","author":"Pelle","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106297_bib0018","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106297_bib0019","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther","volume":"12","author":"Prosperini","year":"2019","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106297_bib0020","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s13365-017-0561-9","article-title":"Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy","volume":"23","author":"Prosperini","year":"2017","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.msard.2025.106297_bib0021","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s13760-024-02480-6","article-title":"Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis","volume":"124","author":"Rabea","year":"2024","journal-title":"Acta. Neurol. Belg."},{"key":"10.1016\/j.msard.2025.106297_bib0022","first-page":"28","article-title":"Disease-modifying therapies in multiple sclerosis: overview and treatment considerations","volume":"33","author":"Robertson","year":"2016","journal-title":"Fed. Pract."},{"key":"10.1016\/j.msard.2025.106297_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104561","article-title":"Exploratory clinical efficacy and patient-reported outcomes from NOVA: a randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis","volume":"72","author":"Ryerson","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106297_bib0024","unstructured":"World Health Organization, 2023. Multiple sclerosis. www.who.int\/news-room\/fact-sheets\/detail\/multiple-sclerosis (accessed 1 December 2023)."},{"key":"10.1016\/j.msard.2025.106297_bib0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106297_bib0026","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T02:04:25Z","timestamp":1739498665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"alternative-id":["S2211034825000410"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106297","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106297"}}